iShares US Healthcare E.T.F. (IYH) Buy, Sell…

Home

Daily Stock Opinions and Ratings

iShares US Healthcare E.T.F. (IYH)

72.31

-0.32 (0.44%)

as of Aug 28, 2026, 8:00:00 pm Market Open.

20 watching

Investor Insights

Aug 30, 2026, 12:00 am

This summary was created by AI, based on 1 opinions in the last 12 months.

The iShares US Healthcare ETF (IYH-N) is currently receiving positive reviews from experts, particularly in light of recent developments impacting the healthcare sector. Analysts highlight improvements in Medical Loss Ratio (MLR) expectations for managed-care companies, which suggests a potential for improved profitability and operational efficiency in the sector. Additionally, there is optimism regarding the clarity around Medicare Advantage, which could further benefit managed-care providers and thereby influence the performance of the ETF. These factors indicate a potentially favorable environment for investment in the healthcare sector, especially for funds like IYH-N that focus on healthcare companies. Investors are encouraged to consider these developments when evaluating the ETF's potential in relation to its peers.

Consensus

Positive

Valuation

Fair Value

Similar

CVA

COMMENT

Healthcare tends to be a little less correlated to the equity market, so it is an ideal place to be. We are approaching the seasonal strength for biotech at the end of June. The chart on this is showing higher lows and higher highs. A similar one, but hedged to the Cdn$, would be BMO Equal Weight US Healthcare (ZUH-T). (See Top Picks.)

Wealthica Track your Stocks in your Watch List

BUY

Owns all the large US healthcare names. Continues to move along at a very nice clip.

BUY

This has big holdings in things like Johnson & Johnson (JNJ-N), Pfizer (PFE-N), Merck (MRK-N), etc. Has done very well year to date.

BUY ON WEAKNESS

Likes this area. Going forward, it will be a defensive space. Broke out past its previous resistance point. If you own, Hold. You could add to that on pullbacks.

BUY

Have liked the sector for quite awhile. Has outperformed the S & P 500 since the beginning of the year. Very heavily weighted to large pharma. Short term there's a little bit of a risk, but long term, it's a place you want to have exposure to.

Showing 16 to 20 of 20 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Capital Wealth Planning

Jim Lebenthal

Cerity Partners

Bill Baruch, Founder, Blue Line Capital

Blue Line Capital

Brianne Gardner

Raymond James

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

iShares US Healthcare E.T.F. (IYH)